Lucassin (Ikaria) is approved for Hepatorenal Syndrome in Australia

Australian regulators have approved Lucassin (terlipressin) from Ikaria Australia for the treatment of Hepatorenal Syndrome type 1 (HRS 1) in patients who are actively being considered for a liver transplant, making it the first approved treatment for HRS 1. The product is already approved in France, Ireland, Spain and South Korea for this indication. In the US and Canada it is in an ongoing pivotal Phase III study, (REVERSE study), evaluating the efficacy and safety of Lucassin in HRS 1 patients